FORMYCON AG (FYB.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:FYB - DE000A1EWVY8 - Common Stock
22.75 EUR
-0.4 (-1.73%)
Overall FYB gets a fundamental rating of 3 out of 10. We evaluated FYB against 78 industry peers in the Biotechnology industry. FYB has a bad profitability rating. Also its financial health evaluation is rather negative. FYB is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
FYB had negative earnings in the past year.
In the past year FYB had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: FYB reported negative net income in multiple years.
FYB had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
FYB has a Return On Assets (-22.86%) which is comparable to the rest of the industry.
FYB's Return On Equity of -41.58% is fine compared to the rest of the industry. FYB outperforms 64.10% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -22.86% | ||
| ROE | -41.58% | ||
| ROIC | N/A |
ROA(3y)-1.19%
ROA(5y)-6.14%
ROE(3y)-0.68%
ROE(5y)-7.18%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
FYB does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
FYB does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for FYB has been increased compared to 1 year ago.
Compared to 5 years ago, FYB has more shares outstanding
FYB has a better debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of 1.41, we must say that FYB is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 1.41, FYB is in the better half of the industry, outperforming 67.95% of the companies in the same industry.
A Debt/Equity ratio of 0.02 indicates that FYB is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.02, FYB is in the better half of the industry, outperforming 73.08% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1.41 |
ROIC/WACCN/A
WACC7.08%
2.3 Liquidity
A Current Ratio of 1.54 indicates that FYB should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.54, FYB is in line with its industry, outperforming 44.87% of the companies in the same industry.
A Quick Ratio of 1.51 indicates that FYB should not have too much problems paying its short term obligations.
Looking at the Quick ratio, with a value of 1.51, FYB is in line with its industry, outperforming 47.44% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.54 | ||
| Quick Ratio | 1.51 |
3. Growth
3.1 Past
FYB shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -339.98%.
The Revenue for FYB has decreased by -14.84% in the past year. This is quite bad
Measured over the past years, FYB shows a quite strong growth in Revenue. The Revenue has been growing by 15.48% on average per year.
EPS 1Y (TTM)-339.98%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-425.42%
Revenue 1Y (TTM)-14.84%
Revenue growth 3Y23.92%
Revenue growth 5Y15.48%
Sales Q2Q%0.03%
3.2 Future
The Earnings Per Share is expected to grow by 39.44% on average over the next years. This is a very strong growth
Based on estimates for the next years, FYB will show a very strong growth in Revenue. The Revenue will grow by 22.94% on average per year.
EPS Next Y-125.05%
EPS Next 2Y29.06%
EPS Next 3Y39.44%
EPS Next 5YN/A
Revenue Next Year-8.28%
Revenue Next 2Y23.67%
Revenue Next 3Y34.17%
Revenue Next 5Y22.94%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
FYB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year FYB is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
93.59% of the companies in the same industry are more expensive than FYB, based on the Enterprise Value to EBITDA ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 3.42 |
4.3 Compensation for Growth
A more expensive valuation may be justified as FYB's earnings are expected to grow with 39.44% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y29.06%
EPS Next 3Y39.44%
5. Dividend
5.1 Amount
FYB does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
FRA:FYB (11/24/2025, 5:28:20 PM)
22.75
-0.4 (-1.73%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners9.42%
Inst Owner ChangeN/A
Ins Owners3.28%
Ins Owner ChangeN/A
Market Cap401.99M
Revenue(TTM)51.78M
Net Income(TTM)-169.77M
Analysts82.86
Price Target52.63 (131.34%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)13.28%
Min Revenue beat(2)-63.69%
Max Revenue beat(2)90.24%
Revenue beat(4)2
Avg Revenue beat(4)18.75%
Min Revenue beat(4)-63.69%
Max Revenue beat(4)90.24%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-121.05%
EPS NY rev (1m)0%
EPS NY rev (3m)-19.77%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-50%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.34%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 7.76 | ||
| P/FCF | N/A | ||
| P/OCF | 27.23 | ||
| P/B | 0.98 | ||
| P/tB | N/A | ||
| EV/EBITDA | 3.42 |
EPS(TTM)-9.6
EYN/A
EPS(NY)-0.32
Fwd EYN/A
FCF(TTM)-1.26
FCFYN/A
OCF(TTM)0.84
OCFY3.67%
SpS2.93
BVpS23.11
TBVpS-2.71
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -22.86% | ||
| ROE | -41.58% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-1.19%
ROA(5y)-6.14%
ROE(3y)-0.68%
ROE(5y)-7.18%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.07
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 0.08 | ||
| Cap/Depr | 24.47% | ||
| Cap/Sales | 71.59% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 12.89% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.54 | ||
| Quick Ratio | 1.51 | ||
| Altman-Z | 1.41 |
F-Score3
WACC7.08%
ROIC/WACCN/A
Cap/Depr(3y)860.64%
Cap/Depr(5y)536.06%
Cap/Sales(3y)44.41%
Cap/Sales(5y)27.51%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-339.98%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-425.42%
EPS Next Y-125.05%
EPS Next 2Y29.06%
EPS Next 3Y39.44%
EPS Next 5YN/A
Revenue 1Y (TTM)-14.84%
Revenue growth 3Y23.92%
Revenue growth 5Y15.48%
Sales Q2Q%0.03%
Revenue Next Year-8.28%
Revenue Next 2Y23.67%
Revenue Next 3Y34.17%
Revenue Next 5Y22.94%
EBIT growth 1Y-49.54%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-132.11%
EBIT Next 3Y112.12%
EBIT Next 5Y72.19%
FCF growth 1Y58.76%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y186.39%
OCF growth 3YN/A
OCF growth 5YN/A
FORMYCON AG / FYB.DE FAQ
What is the ChartMill fundamental rating of FORMYCON AG (FYB.DE) stock?
ChartMill assigns a fundamental rating of 3 / 10 to FYB.DE.
Can you provide the valuation status for FORMYCON AG?
ChartMill assigns a valuation rating of 2 / 10 to FORMYCON AG (FYB.DE). This can be considered as Overvalued.
What is the profitability of FYB stock?
FORMYCON AG (FYB.DE) has a profitability rating of 1 / 10.
What is the financial health of FORMYCON AG (FYB.DE) stock?
The financial health rating of FORMYCON AG (FYB.DE) is 3 / 10.
What is the earnings growth outlook for FORMYCON AG?
The Earnings per Share (EPS) of FORMYCON AG (FYB.DE) is expected to decline by -125.05% in the next year.